TREVI THERAPEUTICS INC (TRVI)
US89532M1018 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 401.44% | N/A 2,414.91% | N/A 191.41% | N/A 144.99% | N/A 52.57% | |||||||||
| EBITDA YoY % growth | -8.63M | -8.24M 4.52% | -18.39M -123.18% | -26.61M -44.70% | -32.44M -21.91% | -32.43M 0.03% | -29.87M 7.89% | -33.8M -13.16% | N/A -61.51% | N/A -21.70% | N/A -31.77% | N/A -5.73% | N/A 110.85% | N/A 1,138.40% | N/A 81.40% | N/A | |
| EBIT YoY % growth | -8.63M | -8.24M 4.52% | -18.41M -123.42% | -26.65M -44.76% | -32.49M -21.91% | -32.48M 0.03% | -29.91M 7.91% | -33.923M -13.42% | N/A -59.52% | N/A -14.80% | N/A -18.21% | N/A -4.20% | N/A 82.83% | N/A 1,081.82% | N/A 249.39% | N/A 62.39% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -1.81 9.58% | -1.52 16.02% | -0.56 63.16% | -0.29 48.21% | N/A -71.80% | N/A 0.59% | N/A -6.58% | N/A 10.78% | N/A 121.23% | N/A 985.71% | N/A 185.34% | N/A 47.81% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.13 -57.14% | -0.12 -13.59% | -0.12 -4.13% | -0.12 3.88% | -0.14 -11.56% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -14.522M -64.83% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.171M -58.63% | -15.258M -28.15% | -16.186M -21.80% | -16.898M -19.96% | -18.045M -27.34% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.13 -62.50% | -0.12 | -0.01 | -7.61% |
| Q2 2024 Q2Q % growth | -0.12 -71.43% | -0.11 | -0.01 | -10.99% |
| Q1 2024 Q2Q % growth | -0.11 -83.33% | -0.09 | -0.02 | -22.55% |
| Q4 2023 Q2Q % growth | -0.08 -33.33% | -0.09 | 0.01 | 14.44% |
| Q3 2023 Q2Q % growth | -0.08 33.33% | -0.09 | 0.01 | 14.44% |
| Q2 2023 Q2Q % growth | -0.07 50.00% | -0.09 | 0.02 | 19.26% |
| Q1 2023 Q2Q % growth | -0.06 75.00% | -0.07 | 0.01 | 19.78% |
| Q4 2022 Q2Q % growth | -0.06 78.57% | -0.11 | 0.05 | 43.98% |
| Q3 2022 Q2Q % growth | -0.12 64.71% | -0.14 | 0.02 | 12.85% |
| Q2 2022 Q2Q % growth | -0.14 70.21% | -0.19 | 0.05 | 25.51% |
| Q1 2022 Q2Q % growth | -0.24 44.19% | -0.29 | 0.05 | 17.92% |
| Q4 2021 Q2Q % growth | -0.28 45.10% | -0.30 | 0.02 | 7.57% |
| Q3 2021 Q2Q % growth | -0.34 17.07% | -0.41 | 0.07 | 16.14% |
| Q2 2021 Q2Q % growth | -0.47 -14.63% | -0.47 | 0.00 | -0.61% |
| Q1 2021 Q2Q % growth | -0.43 10.42% | -0.53 | 0.10 | 18.93% |
| Q4 2020 Q2Q % growth | -0.51 2.44% | -0.45 | -0.06 | -12.78% |
| Q3 2020 Q2Q % growth | -0.41 | -0.52 | 0.11 | 21.57% |
| Q2 2020 Q2Q % growth | -0.41 34.92% | -0.49 | 0.08 | 16.69% |
| Q1 2020 Q2Q % growth | -0.48 96.53% | -0.45 | -0.03 | -6.83% |
| Q3 2019 Q2Q % growth | -0.41 | -0.48 | 0.07 | 15.38% |
| Q2 2019 Q2Q % growth | -0.63 | -0.42 | -0.21 | -50.10% |
| Q1 2019 Q2Q % growth | -13.85 | -0.53 | -13.32 | -2,498.74% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -20.13% | 0.22% | -4.44% |
| Revenue | N/A | N/A | N/A | N/A |